Article information
Full text is only aviable in PDF
References
[1.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, et al.
Comparison off upper gastrointestinal toxicity of rofecoxib and naproxen in patients with arthritis rheumatoid.
N Engl J Med, 343 (2000), pp. 1520-1528
[2.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al.
Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflam-matory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial.
JAMA, 284 (2000), pp. 1247-1255
[3.]
G.A. FitzGerald.
COX-2 and beyond: approaches to prostaglandin inhibition in human disease.
Nat Rev Drug Discov, 2 (2003), pp. 879-890
[4.]
D. Mukherjee, S.E. Nissen, E.J. Topol.
Risk of cardiovascular events associated with selective COX-2 inhibitors.
JAMA, 286 (2001), pp. 954-959
[5.]
M.A. Konstam, M.R. Weir, A. Reicin, D. Shapiro, R.S. Sperling, E. Barr, et al.
Cardiovascular thrombotic events in controlled, clinical trials ofrofecoxib.
Circulation, 104 (2001), pp. 2280-2288
[6.]
L.J. Crofford.
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?.
Current Op Rheum, 14 (2002), pp. 225-230
[7.]
D. Solomon, S. Schneeweiss, R. Glynn, Y. Kiyota, R. Levin, H. Mogun.
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Circulation, 109 (2004), pp. 2068-2073
[8.]
S.R. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, et al.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
N Engl J Med, 352 (2005), pp. 1092-1102
[9.]
S.D. Solomon, J.J.V. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, et al.
Cardiovascular risk associated with celecoxib in a clinical trial for colo-rectal adenoma prevention.
N Engl J Med, 352 (2005), pp. 1071-1080
[10.]
N. Agrawal, A.G. Porras, C.Z. Matthews, E.S. Woolf, J.L. Miller, S. Mukhopadhyay, et al.
Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers.
J Clin Pharmacol, 41 (2001), pp. 1106-1110
[11.]
H.R.J. Schumacher, J. Boice, D. Daikh, S. Mukhopadhyay, K. Malnstrom, S. Ng, et al.
Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.
BMJ, 324 (2002), pp. 1488-1492
[12.]
K. Gottesdiener, T. Schnitzer, C. Fisher, B. Bockow, J. Markenson, A. Ko, et al.
Results of a randomized, dose ranging trial of etoricoxib in patients with osteoarthritis.
Rheumatology (Oxford), 41 (2002), pp. 1052-1061
[13.]
A.K. Matsumoto, A. Melian, D.R. Mandel, H.H. Mcllwain, D. Borenstein, P.L. Zhao.
A randomized controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
J Rheumatol, 29 (2002), pp. 1623-1630
[14.]
Baraf HSV, Fuentesalba C, Greenwald M, et al. Gastrointestinal tolerability and effectiveness of etoricoxib compared with diclofenac sodium in patients with osteoarthritis. A randomized, blinded, clinical study. Press conference presented in American College of Rheumatology. 68.° Annual Scientific Meeting. San Antonio, Texas. USA; October 16-21, 2004.
[15.]
W. Makaraowski, W.W. Zhao, T. Bevirt, D.P. Recker.
Efficacy and safety ofthe COX 2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double blind, placebo controlled comparison with naproxen.
Osteoarthritis Cartilage, 10 (2002), pp. 290-296
[17.]
E. Ott, N.A. Nussmeier, P.C. Duke.
Efficacy and safety of the cYclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.
J Thorac Cardiovasc Surg, 127 (2004), pp. 605
[18.]
N.A. Nussmeier, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, et al.
Complications ofthe COX-2 inhibitors parecoxib and valdecoxib alter cardiac surgery.
N Engl J Med, 352 (2005), pp. 1081-1091
[19.]
T.J. Schnitzer, G.R. Burmester, E. Mysler, M.C. Hochberg, M. Doherty, E. Ehrsam, et al.
Comparison oflumiracoxib with naproxen and ibuprofen in the Therapeutic Artritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Lancet, 364 (2004), pp. 665-674
[20.]
M.E. Farkouh, H. Kirshner, R.A. Harrington, S. Ruland, F.W. Verheugt, T.J. Schnitzer, et al.
Comparison oflumiracoxib with naproxen and ibuprofen in the Therapeutic Artritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Lancet, 364 (2004), pp. 675-684
[21.]
B.F. McAdam, F. Catella-Lawson, L.A. Mardini, S. Kapoor, J.A. Lawson, G.A. FitzGerald.
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
Proc Natl Acad Sci U S A, 96 (1999), pp. 272-277
[22.]
G.A. FitzGerald, C. Patrono.
The coxibs, selective inhibitors of cyclooxygenase-2.
N Engl J Med, 345 (2001), pp. 433-441
[23.]
G.A. FitzGerald, Y. Cheng, S. Austin.
COX-inhibitors and the cardiovascular system.
Clin Exp Rheumatol, 19 (2001), pp. S31-S36
[24.]
J.L. Wallace, W. Mc Knight, B.K. Reuter, N. Vergnolle.
NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.
Gastroenterology, 119 (2000), pp. 706-714
[25.]
C. Baigent, C. Patrono.
Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease.
Arthritis Rheum, 48 (2003), pp. 12-20
[26.]
A.J. Marcus, M.J. Broekman, J.H. Drosoupolos, D.J. Pinsky, N. Islan, C.R. Maliszewsk.
Inhibition of platelet recruitment by endothelial cell CD30/ecto-ADPase: significance for occlusive vascular diseases.
Ital Heart J, 2 (2001), pp. 824-830
[27.]
M. Cicmil, J.M. Thomas, M. Leduc, C. Bon, J.M. Gibbins.
Platelet endothelial cell adhesion molecule-1 signalling inhibits the activation of human platelets.
Blood, 99 (2002), pp. 137-144
[28.]
D. Mukhetjee, S.E. Nissen, E.J. Topol.
Risk of cardiovascular events associated with selective COX-2 inhibitors.
JAMA, 286 (2001), pp. 954-959
[29.]
G.A. FitzGerald.
COX-2 and beyond :approaches to prostaglandin inhibition in human disease.
Nat Rev Drug Discov, 2 (2003), pp. 879-890
[30.]
D. Bulut, T.S. Liagha, C. Hanefeld, R. Koll, T. Miebach, A. Mügge.
Selective cyclooxygenase-2 inhibition with parecoxib acutely impairs endothe-liumdependent vasodilatation in patients with essential hypertension.
J Hyp, 21 (2003), pp. 1663-1667
[31.]
E. Collantes, S.P. Curtis, K.W. Lee, N. Casas, T. McCarthy, A. Melian.
A multinational randomised, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
BMC Family Practice, 3 (2002), pp. 10
[32.]
A. van Hecken, J.I. Schwartz, M. Depre, et al.
Comparative Inhibitory activity of rofecoxib, meloxicam,diclofenac, ibuprofen and naproxen on COX2 versus COX-1 in healthy volunteers.
J Clin Pharmacol, 40 (2000), pp. 1109-1120
[33.]
E. Rahme, L. Pilote, J. LeLorier.
Association between naproxen use and protection against acute myocardial infarction.
Arch Intern Med, 162 (2002), pp. 1111-1115
[34.]
D.J. Watson, T. Rhodes, B. Cai, et al.
Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.
Arch Intern Med, 162 (2002), pp. 1105-1110
[35.]
D.H. Solomon, R.J. Glynn, R. Levin.
Nonsteroidal anti-inflamatory drug use and acute myocardial infarction.
Arch Intern Med, 162 (2002), pp. 1099-1104
[36.]
W.A. Ray, C.M. Stein, K. Hall.
Non-streroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.
Lancet, 359 (2002), pp. 118-123
Copyright © 2008. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
